A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma
Status:
Active, not recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This is an open-label Phase 1b study designed to evaluate the tolerability and safety of
lenvatinib in combination with pembrolizumab in participants with hepatocellular carcinoma
(HCC). The study will evaluate objective response rate and duration of response by modified
Response Evaluation Criteria In Solid Tumors (mRECIST) for HCC and Response Evaluation
Criteria In Solid Tumors (RECIST 1.1) based on independent imaging review (IIR).